Headlines about Aldeyra Therapeutics (NASDAQ:ALDX) have trended somewhat negative this week, according to Accern. The research firm ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aldeyra Therapeutics earned a media sentiment score of -0.11 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.3025224256793 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Aldeyra Therapeutics (NASDAQ:ALDX) opened at $6.55 on Tuesday. Aldeyra Therapeutics has a fifty-two week low of $3.80 and a fifty-two week high of $11.90. The stock has a market capitalization of $125.22, a P/E ratio of -4.65 and a beta of 0.53. The company has a debt-to-equity ratio of 0.02, a current ratio of 20.35 and a quick ratio of 20.35.
Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. analysts anticipate that Aldeyra Therapeutics will post -1.39 earnings per share for the current fiscal year.
A number of equities analysts recently issued reports on ALDX shares. ValuEngine raised Aldeyra Therapeutics from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 12th. Canaccord Genuity reissued a “buy” rating and issued a $27.00 price objective (up from $12.00) on shares of Aldeyra Therapeutics in a report on Wednesday, September 13th. Cowen reissued an “outperform” rating and issued a $14.00 price objective (up from $9.00) on shares of Aldeyra Therapeutics in a report on Thursday, September 14th. Zacks Investment Research lowered Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. Finally, Cantor Fitzgerald started coverage on Aldeyra Therapeutics in a report on Tuesday, October 24th. They issued an “overweight” rating and a $22.00 price objective for the company. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Aldeyra Therapeutics presently has a consensus rating of “Buy” and an average target price of $17.42.
TRADEMARK VIOLATION WARNING: “Aldeyra Therapeutics (ALDX) Getting Somewhat Critical Media Coverage, Accern Reports” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/09/aldeyra-therapeutics-aldx-getting-somewhat-critical-media-coverage-accern-reports.html.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.